Adeno-associated viral vector serotype 5 poorly transduces liver in rat models

Paula S. Montenegro-Miranda, Astrid Pañeda, Lysbeth ten Bloemendaal, Suzanne Duijst, Dirk R. de Waart, Gloria Gonzalez Aseguinolaza, Piter J. Bosma

Research output: Contribution to JournalArticleAcademicpeer-review

18 Citations (Scopus)

Abstract

Preclinical studies in mice and non-human primates showed that AAV serotype 5 provides efficient liver transduction and as such seems a promising vector for liver directed gene therapy. An advantage of AAV5 compared to serotype 8 already shown to provide efficient correction in a phase 1 trial in patients suffering from hemophilia B, is its lower seroprevalence in the general population. Our goal is liver directed gene therapy for Crigler-Najjar syndrome type I, inherited severe unconjugated hyperbilirubinemia caused by UGT1A1 deficiency. In a relevant animal model, the Gunn rat, we compared the efficacy of AAV 5 and 8 to that of AAV1 previously shown to be effective. Ferrying a construct driving hepatocyte specific expression of UGT1A1, both AAV8 and AAV1 provided an efficient correction of hyperbilirubinemia. In contrast to these two and to other animal models AAV5 failed to provide any correction. To clarify whether this unexpected finding was due to the rat model used or due to a problem with AAV5, the efficacy of this serotype was compared in a mouse and two additional rat strains. Administration of an AAV5 vector expressing luciferase under the control of a liver specific promoter confirmed that this serotype poorly performed in rat liver, rendering it not suitable for proof of concept studies in this species
Original languageEnglish
Pages (from-to)e82597
JournalPLoS ONE
Volume8
Issue number12
DOIs
Publication statusPublished - 2013

Cite this